Wednesday, 8th June 21st Lancefield International Symposium for Streptococci and Streptococcal Diseases 2022

• Dr. Ganna Oliynyk - Introduction to Symcel and the calScreener
• Prof Norrby-Teglund - Bacterial Tissue Infections:  Utilization of the calScreener to monitor bacterial growth and antibiotic efficacy 
• Open discussions, questions and networking

Breakfast served from 6:45am

There is no additional cost for this workshop

Click here to watch this session live.

Click here to watch this session live.

Click here to submit questions

• The full societal value of prospective Strep A vaccination - David Bloom

Click here to watch this session live.

Click here to submit questions

• A Human Model of a Human Disease - Joshua Osowicki
• The Australian Strep A Vaccine Initiative - Jonathan Carapetis
• Progress towards vaccines for group B streptococcus - Kirsty Le Doare

Click here to watch this session live.

Click here to submit questions

• The amino acid asparagine as a mediator of cross-talk between the host and the pathogen - Emanuel Hanski
• This talk will be delivered by Mark Walker  - Edmund Loh
• Molecular Mimicry of Host Cell Surfaces in Streptococcal Immune Evasion and Anti-Infective Nano-Therapeutics    - Victor Nizet

• Interactions of clinical Streptococcus pyogenes of different genotypes with human tonsil infection models - Henna Khalid
• Isothermal microcalorimetry to monitor antibiotic treatment of bacterial tissue infections and in-tissue biofilm - Kirsten Moll
• Complement factor H-binding by streptococcal collagen-like protein 1 and M protein from M6-type group A Streptococcus confer survival advantage in human blood - Slawomir Lukomski
• Group A Streptococcus effector NAD-glycohydrolase causes Golgi fragmentation to impair hots immune systems - Takashi Nozawa
• Carbohydrate metabolism and niche competition by Streptococcus pyogenes - Amanda Marple
• Adaptation of the Group A Streptococcus – phage A25 virocell to the human host - Lionel Schiavolin
• Association between streptococcal pyrogenic exotoxin A (SpeA) expression and transcriptional regulatory gene mutations in streptococcus pyogenes - Ho Kwong Li
• Platelet activation and accumulation in organs during invasive infection with Streptococcus pyogenes - Eleni Bratanis
• The role of streptolysin O and streptolysin S in Streptococcus pyogenes infection in HLA-transgenic mice - Blake A Shannon
• Expression of UDP-N-acetylglucosamine transporter, SLC35A3, and susceptibility to invasive Streptococcus pyogenes infection - Tom Parks
• Hyper-virulent Streptococcus pyogenes impairs interleukin-18 response in human immune cells of myeloid lineage - Lea A. Toelken
• Anticoagulant influence on whole blood killing assay - Corentin Bruyns
• Immune privileged sites give Streptococcus pyogenes M protein mutants a fitness advantage - Kristin K Huse
• Lessons learnt from using a machine learning (ML)-based genotype-phenotype association study (GPAS) to predict the metadata of group A Streptococcus (GAS) genomes - Sean J Buckley
• FabT, the Streptococcus pyogenes fatty acid synthesis pathway transcriptional regulator involved in bacterial adaptation to its environment. - Clara Lambert
• Characterization of the protein cargo and pro-inflammatory effects of extracellular vesicles released from pathogen activated platelets - Frida Palm
• Structure of group A streptococcal M3 protein in complex with collagen - Uli Schwarz-Linek
• Group A streptococcus (GAS) Virulence factors associated with invasive disease:  A systematic review - Mark E Engel
• Correlations of virulence genes to clinical manifestations in patients with GAS emm 92 infection. - Kimona Rampersadh
• Characterization of the virulence of a highly necrotizing strain of Streptococcus pyogenes - Geoffrey Deneubourg
• Biomaterial potential of Streptococcal collagen-like (Scl) protein - Anuradha Chakraborti
• Transcriptome analysis of Streptococcus pyogenes in biopsies from patients with monomicrobial necrotizing soft tissue infections   - Jesus M Eraso
• Understanding Natural Immunity to Streptococcus A Infections using validated Opsonophagocytic killing assays. - Reuben McGregor
• The specific interaction of CC17 hypervirulent clone of Group B Streptococcus with phagocytes - Julie Guignot
• The global transcriptional regulator CodY is essential for in vivo virulence of Group B Streptococcus - Angelica Pellegrini
• The impact of the metabolic landscape of the human gastrointestinal tract on pathogenesis of Streptococcus gallolyticus - Aisling Corbet
• Development of a Genetically Modified Organism based on Lactococcus lactis bacterial strain that expresses the Immunogenic Surface Protein of Streptococcus agalactiae - Boris S Riveros-Rodriguez
• Obtaining a strain of Streptococcus agalactiae mutant SIP and in vitro analysis of adhesion and cell invasion - Daniel F Escobar
• StkP- and PhpP-mediated post-translational modification of ccpA modulates the pneumococcus capsule production and virulence - Vijay Pancholi
• Identification and characterization of the putative tryptophan substrate-binding protein TrpA in Streptococcus suis - Muriel Dresen
• The importance of the RGD motif of Streptococcal protein IdeC in Streptococcus canis infection - Saoirse Walsh
• The Streptococcus agalactiae R3 surface protein is encoded by sar5 - Camilla Olaisen
• Correlation of opsonophagocytic killing titers in whole blood vs. HL-60 assays using human serum obtained following immunization with 30-valent Strep A M protein vaccine - Sanaz Salehi
• Rational design of a broadly cross-reactive multivalent group A streptococcal M protein-based vaccine - James B Dale
• A Study in Scarlet: unravelling the historical threads of Streptococcus pyogenes vaccination - Hannah R Frost
• Distribution of GBS protein vaccine targets in disease-causing GBS in the UK - Elita Jauneikaite
• Sublingual vaccine administration in pregnancy: a possible route for maternal immunisation to prevent neonatal Group B streptococcus infection? - Arif Felek
• Optimal global spending for group a streptococcus vaccine research and development - Daniel L Tortorice
• The global health and economic benefits of prospective Strep-A vaccines. - Maddalena Ferranna
• The full societal value of vaccination: Framework and application to group A Streptococcus - Daniel Cadarette
• Design of an effective glycoconjugate vaccine against Group A Streptococcus - Roberta Di Benedetto
• Development of a glycoconjugate vaccine against group a streptococcus (gas) - Keira K Burns
• Characterisation of Streptococcus pyogenes reference strains - Serene Yeow
• Recombinant glycoconjugate vaccine production platform to combat Group A, C and G streptococcal infections - Helge C Dorfmueller
• Structure-based design of a broadly cross-reactive multivalent M protein-based Strep A vaccine: peptide cross-reactive antibody predictions vs. observed levels in immune sera - Thomas A Penfound
• Global cost-effectiveness analysis of a hypothetical Strep A vaccine for various infections caused by Streptococcus pyogenes - Jung-Seok Lee
• Increased breadth of group A Streptococcus antibody responses in children with acute rheumatic fever compared to precursor pharyngitis and skin infections - Alana L Whitcombe
• Subcutaneous infusions of high-dose benzathine penicillin G (SCIP) is safe, tolerable and potentially suitable for less frequent dosing for rheumatic heart disease secondary prophylaxis - Joseph H Kado
• IgG2 and Th17/Th1 cooperation promote the autoimmune pathogenesis of acute rheumatic fever - Madeleine W Cunningham
• Evaluation of GAS vaccine peptides to induce valvulitis and neurobehavioural disorders in a rodent model of rheumatic heart disease. - Simone Reynolds
• Angicin, a novel bacteriocin of Streptococcus anginosus - Verena Vogel

Click here to watch this session live.

• MANUFACTURE OF A GMP-LIKE BACTERIAL CHALLENGE AGENT IN A RESEARCH FACILITY FOR USE IN HUMANS - Kristy I Azzopardi
• Group A Streptococcus-derived vesicles as an antigen presenting platform for vaccine development - Meztlli Gaytan
• Nephritogenic activity of IgA-binding Streptococcus pyogenes: an experimental model of IgA nephropathy - Alexander Suvorov
• Experimental glomerulonephritis in rabbits induced by Streptococcus pyogenes on a model of implanted tissue cages - Alexander Suvorov
• Salivary glycan dynamics during experimental human Streptococcus pyogenes pharyngitis - Anuk Indraratna
• Streptococcus pyogenes hijacks host glutathione for growth and innate immune evasion - Stephan Brouwer
• Longitudinal assessment of serum immune responses to group A streptococcal (GAS) antigens following new pharyngeal acquisitions: an AFROStrep pilot study, Cape Town, South Africa - Taariq Salie
• Molecular characterisation of the interaction between human IgG and M-related proteins from Streptococcus pyogenes. - Emma-Jayne Proctor
• Streptolysins are the primary inflammasome activators in macrophages during Streptococcus pyogenes infection - Johanna Richter
• The role of M-protein in oncolytic activity of S. pyogenes type emm111 - Alexander Suvorov
• Clearance of group B streptococcal infection crucially depends on neutrophil recognition of two distinctive sets of bacterial formylated peptides - Giuseppe Teti
• The copper resistome of group B Streptococcus reveals insight into the genetic basis of cellular survival during metal ion stress - Kelvin GK Goh
• Adherence of Streptococcus equi ssp. zooepidemicus to primary cardiac endothelial cells under flow - Dorothea C. Meyland
• Characterization of the third type of cholesterol-dependent cytolysins produced from Streptococcus mitis strains - Atsushi Tabata
• Characterization of Streptococcus suis phase-variable type I restriction-modification system SsuCC20p and its contribution to zoonotic potential - Thomas Roodsant
• The influence of GBS zeta overexpression on E. coli strains - Eugenia Kuleshevich
• A recombinant alpha-like protein subunit vaccine (GBS-NN) provides protection in murine models of Group B Streptococcus infection - Alyssa Brokaw
• Determining the presence and efficacy of memory B-cell protective responses to vaccine based on minimum epitope following experimental Streptococcus pyogenes human pharyngitis - Ailin Lepletier
• Novel chimeric vaccines against streptococcal infections - Alexander Suvorov
• Impact of Alum on immune response induced by a Strep A vaccine - Martina Carducci
• Profiling circulating immunoglobulins and cytokines in Acute Rheumatic Fever patients - Natalie Lorenz
• Preceding group A streptococcus skin and throat infections are individually associated with acute rheumatic fever: evidence from New Zealand - Jane Oliver
• Ethnically Disparate Disease Progression and Outcomes among Acute Rheumatic Fever Patients in New Zealand, 1989–2015 - Jane Oliver
• Risk factors for acute rheumatic fever: a case-control study - Julie Bennett

Click here to watch this session live.

• A trio of M- and M-like proteins present in most group A streptococcal genomes - Anne Botteaux
• Prioritising burden of disease estimation to accelerate group A streptococcal vaccine development: creation of a data purpose framework - Hannah C Moore
• Towards the development of a mucosal vaccine against Streptococcus pyogenes - Victoria Ozberk
• Mucosal delivery of Group A Streptococcus vaccines has benefits over traditional immunisation - Alexandra Shaw

Click here to watch this session live.

Click here to submit questions

• Endothelial cell migration is inhibited by pneumococci under shear stress - Anna Kopenhagen
• Role of suilysin in pathogenesis of porcine respiratory infections caused by Streptococcus suis - Peter Valentin-Weigand
• Understanding Streptococcus canis virulence via population genetics and Transposon Directed Insertion-site Sequencing - Etienne Aubry
• Genomic epidemiology of the multi-host pathogen Streptococcus canis - Davide Pagnossin

Click here to watch this session live.

Click here to submit questions

• Advances on our understanding of Streptococcus pneumoniae immunity using a Controlled Human Pneumococcal Infection model. - Elena Mitsi
• Human mucosal gene expression profiling reveals diverse and transient immune responses during experimental human Streptococcus pyogenes pharyngitis - Alice Halliday
• Serological responses following colonisation with Streptococcus pyogenes among children aged 2 to 4 years in The Gambia - Alexander J Keeley
• Immunoglobulin A responses in saliva during experimental human Streptococcus pyogenes pharyngitis - Hannah R Frost

Click here to watch this session live.

Click here to submit questions

• Rethinking Rheumatic Fever Pathogenesis: the role of Immune Priming and Epitope Spreading - Nikki Moreland
• Complement and immunoglobulin gene regions and susceptibility to rheumatic heart disease across diverse populations - . International Rheumatic Heart Disease Genetics Consortium
• Profiling autoantibody responses in acute rheumatic fever using a multi‑platform approach - Reuben McGregor
• Neurobehavioral and carditis abnormalities in Lewis Rat Autoimmune Valvulitis Model following exposure to streptococcal M proteins - Rukshan Ahamed Mohamed Rafeek

Click here to watch this session live.

Click here to submit questions

• The impact of the COVID-19 pandemic on GAS transmission in England - Theresa Lamagni
• Contemporary estimates of the global burden of group A Streptococcus pharyngitis and a review of surveillance methodology - Jeffrey Cannon
• The changing epidemiology of invasive group A streptococcus in England between 2016 and 2021:  case reduction and shift in the epidemiology - Juliana Coelho
• Strain Concept for Group A Streptococci and the Massive Mixing of M- and T-type Genes - Debra Bessen

Click here to watch this session live.

Click here to submit questions

• Cellulitis and necrotizing soft tissue infections caused by beta-hemolytic streptococci - Trond Bruun
• Reactive oxygen species and hyaluronic acid capsule influence pathology during group A Streptococcal skin infections - Shyra Wilde
• Group A Streptococcus induces GSDMA-dependent pyroptosis in keratinocytes - Christopher LaRock
• Pro-IL-18 secreted by keratinocytes detects the group A streptococcal protease SpeB - Anders F Johnson

Please see the location here: https://goo.gl/maps/WYhYydgBLrwDr5456

If you would like to walk to the location in a group, please meet in the hotel lobby at 6:00pm